3Kume H, Kondo M. lto Y, et al. Effects of sustained release tnlobulerol on asthma control and beta adrenoceptor function [J]. Clin Exp Pharmaeol Physicol,2002,29(12) : 1076- 1083.
4Kato H, Nagata O, Yan:axaki M, et al. Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma[J].Yakugaku Zasshi, 2002,122 ( 1 ) : 57-69.
1[3]Kume H, Kondo M, Ito Y, et al. Effects of Sustained-release Tulobuterol On AsthmaControl and Beta-adrenoceptor Function [ J].Clin-Exp-Pharmacol-Physiol,2002,29 ( 12 ): 1076.
3[5]Nakano Yoshihisa, Horiuchi Tetsuo, Fujivvara Sanae, et al. Percutaneous Preparation of Tulobuterol: US, 5571530 [ P ].1996-11-05.
4[6]Hans R. Hoffmann, Michael Horstmann. Transdermal Therapeutic System Comprising Tulobuterol as Active Substance: US,5254348[ P]. 1993-10-19.
5[7]OtsukaSaburo, NakagawaTakeaki, NakanoYoshihisa. Percutaneous Tulobuterol Preparation and Process for Producing The Same:WO ,9714411 [ P]. 1997-4-24.
6[9]Otsuka Saburo, Hori Mitsuhiko. Percutaneous Aborption Type Preparation Containing Tulobuterol: EP, 0922453 [ P ]. 1999-06-16.
7Uematsu T,Nakano M,Kosuge K,et al.The pharmacokinetics of the beta 2-adrenoceptor agonist,tulobuterol,given transdermally and by inhalation[J].Eur J Clin Pharmacol,1993,44(4):361-364.
8Iikura Y,Uchiyama H,Akimoto K,et al.Pharmacokinetics and pharmacodynamics of the tulobuterol patch,HN-078,in childhood asthma[J].Ann Allergy Asthma Immunol,1995,74(2):147-151.
9De Wasch K,De Brabander H,Courtheyn D.LC-MS-MS to detect and identify four beta-agonists and quantify clenbuterol in liver[J].Analyst,1998,123 (12):2701-2705.
10Thienpont LM,Verhaeghe PG,De Leenheer AP.Measurement of tulobuterol in human plasma by capillary gas chromatography and selected ion monitoring detection[J].Biomed Environ Mass Spectrom,1987,14 (11):613-616.
